Circadian rhythms in ischaemic heart disease: key aspects for preclinical and translational research: position paper of the ESC working group on cellular biology of the heart.


Journal

Cardiovascular research
ISSN: 1755-3245
Titre abrégé: Cardiovasc Res
Pays: England
ID NLM: 0077427

Informations de publication

Date de publication:
20 09 2022
Historique:
received: 29 01 2021
revised: 04 06 2021
accepted: 07 09 2021
pubmed: 11 9 2021
medline: 24 9 2022
entrez: 10 9 2021
Statut: ppublish

Résumé

Circadian rhythms are internal regulatory processes controlled by molecular clocks present in essentially every mammalian organ that temporally regulate major physiological functions. In the cardiovascular system, the circadian clock governs heart rate, blood pressure, cardiac metabolism, contractility, and coagulation. Recent experimental and clinical studies highlight the possible importance of circadian rhythms in the pathophysiology, outcome, or treatment success of cardiovascular disease, including ischaemic heart disease. Disturbances in circadian rhythms are associated with increased cardiovascular risk and worsen outcome. Therefore, it is important to consider circadian rhythms as a key research parameter to better understand cardiac physiology/pathology, and to improve the chances of translation and efficacy of cardiac therapies, including those for ischaemic heart disease. The aim of this Position Paper by the European Society of Cardiology Working Group Cellular Biology of the Heart is to highlight key aspects of circadian rhythms to consider for improvement of preclinical and translational studies related to ischaemic heart disease and cardioprotection. Applying these considerations to future studies may increase the potential for better translation of new treatments into successful clinical outcomes.

Identifiants

pubmed: 34505881
pii: 6368285
doi: 10.1093/cvr/cvab293
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

2566-2581

Subventions

Organisme : British Heart Foundation
ID : CS/14/3/31002
Pays : United Kingdom
Organisme : Department of Health
Pays : United Kingdom

Informations de copyright

Published on behalf of the European Society of Cardiology. All rights reserved. © The Author(s) 2021. For permissions, please email: journals.permissions@oup.com.

Déclaration de conflit d'intérêts

Conflict of interest: P.F. is the founder and CEO of Pharmahungary Group, a group of R&D companies. L.W.V.L. Outside the current work: consultancy fees to UMCU from Abbott, Medtronic, Vifor, and Novartis.

Auteurs

Sandrine Lecour (S)

Department of Medicine, Hatter Institute for Cardiovascular Research in Africa, University of Cape Town, Cape Town, South Africa.

Bastiaan C Du Pré (BC)

Department of Internal Medicine, Erasmus Medical Centre, Rotterdam, The Netherlands.

Hans Erik Bøtker (HE)

Department of Cardiology, Aarhus University Hospital, Aarhus, Denmark.

Bianca J J M Brundel (BJJM)

Department of Physiology, Amsterdam UMC, Vrije Universiteit, Amsterdam Cardiovascular Sciences, Amsterdam, The Netherlands.

Andreas Daiber (A)

Department of Cardiology, Molecular Cardiology, Medical Center of the Johannes Gutenberg University, Mainz, Germany.
German Center for Cardiovascular Research (DZHK), Partner Site Rhine-Main, Mainz, Germany.

Sean M Davidson (SM)

The Hatter Cardiovascular Institute, University College London, London, UK.

Peter Ferdinandy (P)

Department of Pharmacology and Pharmacotherapy, Semmelweis University, Budapest, Hungary.
Pharmahungary Group, Szeged, Hungary.

Henrique Girao (H)

Faculty of Medicine, Univ Coimbra, Coimbra Institute for Clinical and Biomedical Research (iCBR), Center for Innovative Biomedicine and Biotechnology (CIBB), Clinical Academic Centre of Coimbra (CACC), Coimbra, Portugal.

Can Gollmann-Tepeköylü (C)

Department of Cardiac Surgery, Medical University of Innsbruck, Innsbruck, Austria.

Mariann Gyöngyösi (M)

Department of Cardiology, Medical University of Vienna, Waehringer Guertel 18-20, A-1090, Vienna, Austria.

Derek J Hausenloy (DJ)

Cardiovascular & Metabolic Disorders Program, Duke-National University of Singapore Medical School, Singapore, Singapore.
National Heart Research Institute Singapore, National Heart Centre, Singapore, Singapore.
Yong Loo Lin School of Medicine, National University Singapore, Singapore.
The Hatter Cardiovascular Institute, University College London, London, UK.
Cardiovascular Research Center, College of Medical and Health Sciences, Asia University, Taichung City, Taiwan.

Rosalinda Madonna (R)

Institute of Cardiology, University of Pisa, Pisa, Italy.
Department of Internal Medicine, University of Texas Medical School in Houston, Houston, TX, USA.

Michael Marber (M)

King's College London BHF Centre, The Rayne Institute, St Thomas' Hospital, London, UK.

Cinzia Perrino (C)

Department of Advanced Biomedical Sciences, Federico II University, Naples, Italy.

Maurizio Pesce (M)

Unità di Ingegneria Tissutale Cardiovascolare, Centro Cardiologico Monzino, IRCCS, Milan, Italy.

Rainer Schulz (R)

Institute of Physiology, Justus-Liebig University Giessen, Giessen, Germany.

Joost P G Sluijter (JPG)

Department of Cardiology, Experimental Cardiology Laboratory, Regenerative Medicine Center, Circulatory Health Laboratory, University Medical Center Utrecht, Utrecht University, Utrecht, The Netherlands.

Sabine Steffens (S)

Institute for Cardiovascular Prevention, Ludwig-Maximilians-University, Munich, Germany.
German Centre for Cardiovascular Research (DZHK), Partner Site Munich Heart Alliance, Munich, Germany.

Sophie Van Linthout (S)

Berlin Institute of Health Center for Regenerative Therapies & Berlin-Brandenburg Center for Regenerative Therapies (BCRT), Charité, University Medicine Berlin, Berlin 10178, Germany.
German Centre for Cardiovascular Research (DZHK), Partner Site Berlin, Berlin, Germany.

Martin E Young (ME)

Division of Cardiovascular Diseases, Department of Medicine, University of Alabama at Birmingham, Birmingham, AL, USA.

Linda W Van Laake (LW)

Cardiology and UMC Utrecht Regenerative Medicine Center, University Medical Center Utrecht, Utrecht, The Netherlands.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH